WDR81 Gene Cerebellar Ataxia with Mental Retardation and Dysequilibrium Syndrome Type 2 Genetic Test
Test Name: WDR81 Gene Cerebellar Ataxia with Mental Retardation and Dysequilibrium Syndrome Type 2 Genetic Test
Components: Blood or Extracted DNA or One drop Blood on FTA Card
Price: 4400.0 AED
Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery: 3 to 4 Weeks
Method: NGS Technology
Test Type: Neurological Disorders
Doctor: Neurologist
Test Department: Genetics
Pre Test Information: Clinical History of Patient who is going for WDR81 Gene Cerebellar Ataxia with Mental Retardation and Dysequilibrium Syndrome Type 2 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with WDR81 Gene Cerebellar Ataxia with Mental Retardation and Dysequilibrium Syndrome Type 2.
Test Details
The WDR81 gene is associated with cerebellar ataxia with mental retardation and dysequilibrium syndrome type 2 (CAMRQ2), which is a rare genetic disorder that affects the nervous system. CAMRQ2 is characterized by a combination of symptoms including ataxia (uncoordinated movements), intellectual disability, and problems with balance and coordination (dysequilibrium). Other features of the condition may include seizures, delayed speech and language development, and abnormal eye movements.
NGS (next-generation sequencing) genetic testing can be used to identify mutations in the WDR81 gene that are associated with CAMRQ2. This type of testing can detect changes in the DNA sequence of the gene that may be responsible for causing the disorder. NGS testing can be performed using a small sample of blood or saliva, and results are typically available within a few weeks.
Genetic testing for CAMRQ2 can help to confirm a diagnosis, guide treatment decisions, and provide information about the risk of passing the condition on to future generations. It may also be useful for family members of affected individuals who may be at risk of inheriting the mutation. Genetic counseling is recommended for individuals who are considering genetic testing for CAMRQ2.
| Test Name | WDR81 Gene Cerebellar ataxia with mental retardation and dysequilibrium syndrome type 2 Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card o |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Neurological Disorders |
| Doctor | Neurologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for WDR81 Gene Cerebellar ataxia with mental retardation and dysequilibrium syndrome type 2 NGS Genetic DNA Test A Genetic Counselling session to draw a pedigree chart of family members affected with WDR81 Gene Cerebellar ataxia with mental retardation and dysequilibrium syndrome type 2 |
| Test Details | The WDR81 gene is associated with cerebellar ataxia with mental retardation and dysequilibrium syndrome type 2 (CAMRQ2), which is a rare genetic disorder that affects the nervous system. CAMRQ2 is characterized by a combination of symptoms including ataxia (uncoordinated movements), intellectual disability, and problems with balance and coordination (dysequilibrium). Other features of the condition may include seizures, delayed speech and language development, and abnormal eye movements. NGS (next-generation sequencing) genetic testing can be used to identify mutations in the WDR81 gene that are associated with CAMRQ2. This type of testing can detect changes in the DNA sequence of the gene that may be responsible for causing the disorder. NGS testing can be performed using a small sample of blood or saliva, and results are typically available within a few weeks. Genetic testing for CAMRQ2 can help to confirm a diagnosis, guide treatment decisions, and provide information about the risk of passing the condition on to future generations. It may also be useful for family members of affected individuals who may be at risk of inheriting the mutation. Genetic counseling is recommended for individuals who are considering genetic testing for CAMRQ2. |
